Antigenics Inc. (Lexington, MA) Release: Final Data From Phase 1 Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine in Glioma Presented at the Society for Neuro-Oncology’s Annual Meeting

LAS VEGAS & NEW YORK & MOSCOW--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced an oral presentation of final data from a Phase 1 investigator-sponsored trial of the company’s investigational cancer vaccine Oncophage® (vitespen) in recurrent, high-grade glioma at the Society for Neuro-Oncology’s 13th Annual Scientific Meeting in Las Vegas.